Jeremy Gungabeesoon

Immuno-oncology @Sanofi | Previously @BBS_Harvard @PittetLab @MGHCSB

[Jeremy Gungabeesoon @jgungabeesoon]

Excited to share my PhD work in the @PittetLab, published today in @CellCellPress! We show that immunotherapy can expand a distinct interferon-responsive neutrophil state that contributes to successful responses to therapy: https://t.co/IOys2yN0AP

[The Pittet Lab @PittetLab]

❔What is special about an immune system that successfully attacks tumors, compared to one that doesn’t?

Our new study in @CellCellPress led by @jgungabeesoon, @Nich and @Mate_Kiss_ aimed to address this question. A joint work with the great @KleinLabHMS

https://t.co/Mhi4A7QdfR

[The Pittet Lab @PittetLab]

📢 Research Alert! 🧬🔬 🩺 We are super excited that our latest study, led by the great @RubenBill5 & Asa Wirapati, is out: https://t.co/94ScYEro0h
We set out to shed some light on the tumor microenvironment and its impact on cancer progression.
🧵

[ACIR @ACIR_org]

SPOTLIGHT: @BBS_Harvard @PittetLab @jgungabeesoon demonstrated that neutrophils exhibit remarkable plasticity and could acquire an antitumor phenotype in response to immunotherapy. https://t.co/BwckDFV1Yq

[Harvard University @Harvard]

The findings suggest that researchers may be able to manipulate neutrophils to make cancer therapies more effective https://t.co/1nYaqMCB70

[Jeremy Gungabeesoon @jgungabeesoon]

Read more about my PhD work here! @PittetLab @KleinLabHMS

[Harvard Medical School @harvardmed]

Neutrophils — the most common cell type in the immune system — play a key role in immunotherapy success https://t.co/2rSIhvTtmj

[Christopher Garris @csgarrix]

The Garris Lab @MGHCSB @MGH_RI @harvardmed is looking for curious and driven postdoctoral fellows who want to investigate the biology of #dendriticcells in cancer growth and therapy. Interested candidates should send their CV and cover letter to [email protected]

[Jeremy Gungabeesoon @jgungabeesoon]

@ArianaYoum @RyanGosling Congrats ari 👏👏👏

[The Pittet Lab @PittetLab]

1/ 🤩Whoah! I'm so excited to be a part of this awesome @MempelThorsten study, led by @DiPilato and colleagues. It shows a mechanism by which "good" cells (i.e. antitumor CD8 T cells) can survive in tumors to do their job.
https://t.co/N2T3zGKiUR

[Mempel Lab @MempelThorsten]

The intrepid Mauro (now @DiPilatoLab) and team did it again: CXCR6 enables CTL to control tumors by guiding their interactions with CCR7+ cDC in perivascular survival niches of the tumor stroma. Thanks to our fantastic collaborators. See 🧵 for details.
https://t.co/wgXGmqw5Xy

[Cameron McAlpine @cam_phd]

Immune networks within the glial cell ecosystem maintain brain health.

Our latest is out today in @nature. Astrocytic interleukin-3 programs microglia and limits Alzheimer’s disease.

This was a wonderful collaboration with @RudyTanzi and his team. 1/
https://t.co/Bl1nPkk9MA

[Andrés Hidalgo @AndrsHidalgo16]

Are brain borders the new bone marrow?

New work from the @mzhlab complements recent findings from the @TheColonnaLab and @jonykipnis labs to show brain-dedicated B-lymphopoiesis!
A pleasure to contribute our little grain

https://t.co/9DJAQzsKSo

[Marie Siwicki @MarieSiwicki]

It’s out! My PhD work focusing on toxicities associated with anti-cancer immunotherapy drugs:
https://t.co/05zFhK2wNS

And my first #tweetorial brought to you by @PittetLab where you can learn all about our findings! https://t.co/SlsX9GH9Wj

[Science Immunology @SciImmunology]

A new @MGH_RI, @harvardmed study pinpoints a potential target to offset adverse effects from #cancer #immunotherapy, revealing in mice that obstructing inflammatory neutrophils in the liver prevented the toxicity of anti-CD40 agonist therapy: https://t.co/Foih0gnooM

[The Pittet Lab @PittetLab]

👉Macrophages & neutrophils may drive toxicities after #immunotherapy, but NOT dendritic cells. Instead, dendritic cells, incl. DC3 (also called, LAMP3 DC, mregDC) may be key for antitumor immunity. This could be important for next gen treatments.
https://t.co/fcq1a0Y2Td

[The Pittet Lab @PittetLab]

0/ Published today in Science Immunology! Work from our lab investigating immunotherapy-driven toxicities (immune related adverse events, a.k.a. irAEs), which are a major clinical problem in cancer immunotherapy clinics. #tweetorial
https://t.co/GEl2peGJGX

[Christopher Garris @csgarrix]

Pleased to announce my latest study @RockefellerUniv published in @ScienceTM. https://t.co/xktTomFpYy In this study we provide proof of concept for bladder infused CD40 agonistic antibodies as a local treatment for bladder cancer.

[Science Magazine @ScienceMagazine]

Low-carb, high-fat diets—including the popular “ketogenic” diet—may not be any more effective at keeping obesity at bay than those that balance calorie intake with energy expenditure, a new #SciencePerspective suggests. https://t.co/xWIe3Ffxsk #WeekendReads

[Jeremy Gungabeesoon @jgungabeesoon]

@ArianaYoum @NSERC_CRSNG Wooo!!!! 🎉 🙌

[The Pittet Lab @PittetLab]

👉The @PittetLab is hiring a #bioinformatician to pursue our work on the tumor immune microenvironment.

All this in an amazing place https://t.co/X8Kvja4gMS 🇨🇭... and with a great bioinformatics network @KleinLabHMS @carmonation !

Please share or let us know if interested!

[Jeremy Gungabeesoon @jgungabeesoon]

@ArianaYoum Go ari 🙌